A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects

Exclusion Criteria

• •Subjects with a positive test result for hepatitis B, hepatitis C, or HIV
• •Subjects with a significant history of any illness, as deemed important by the investigator or any condition possibly affecting drug absorption
• •Subjects with a positive urine screen for drugs of abuse
• •Subjects with a history of regular alcohol consumption
• •Subjects treated with an investigational drug within 30 days
• •For Part A only: Subjects with 12-lead ECG QTcF \>450 msec (males) or QTcF \>470 msec (females) at the Screening Visit
• •Subjects who use prescription and/or nonprescription medications or vitamins and/or dietary supplements
• •Subjects who have made a blood donation of approximately 1 pint (500 mL) within 56 days prior to the first dose of study drug
• •Subjects who have a female partner who is pregnant, nursing, or planning to become pregnant during the study or within 90 days of the last dose of study drug
• •Subjects on hormone replacement therapy (HRT) must discontinue such therapy 28 days prior to the first dose of study drug
• •Subjects who have a habit of using tobacco or nicotine containing products within 6 months before the Screening Visit